INVEST RADIO:单克隆浆细胞疾病骨髓的ADC和MRI信号强度测量的可重复性

2022-07-16 shaosai MedSci原创

尽管多项指南推荐使用DWI进行多发性骨髓瘤的成像,但迄今为止,关于ADC测量的可重复性相关文献非常有限。

在过去十年中,扩散加权成像(DWI)在单克隆浆细胞疾病(MPCDs)的诊断及评估中应用广泛研究表明表观弥散系数(ADC)在健康对照组和不同阶段的MPCD之间存在差异,在病灶(FLs)、弥漫性骨髓(BM)浸润和正常BM之间也存在差异。此外,ADC与BM浆细胞浸润(PCI)相关,可用于显示弥漫性浸润或评估治疗反应。除了ADC,高b值图像和形态学的T1加权(T1w)涡轮自旋回波和T2w短TI反转恢复的(组织归一化)信号强度(SI)也被证明与PCI相关。

尽管多项指南推荐使用DWI进行多发性骨髓瘤的成像,但迄今为止,关于ADC测量的可重复性相关文献非常有限。近日,发表在INVEST RADIO杂志的一项研究在实际的MPCD患者中,探讨了体内BM的ADC和MR-SI的可重复性和测量者之间的可重复性,并量化了多中心研究数据中观察到的扫描器间和协议间的可重复性,并研究了ADC/SI的简单标准化方法的潜力。

本研究纳入了55名疑似或确诊的单克隆浆细胞疾病患者,并在标准的临床全身MR扫描后进行了多项测量,包括重新定位后的重复扫描、第二台MRI方案扫描、在第二台1.5T扫描仪上使用统一的MRI方案扫描以及在3T扫描仪上扫描。对于T1加权、T2加权STIR、B800图像和ADC图,感兴趣的区域被放置在髂嵴和骶骨的BM中,以及肌肉组织中以进行图像标准化。构建了Bland-Altman图,并计算了绝对偏差、与平均值的相对偏差、协议极限和变异系数。 

双方差异性和重复性实验显示,所有序列的最大相对偏差为-0.077,最大变异系数为16.2%。尽管在第二台1.5T扫描仪上,与第一台1.5T扫描仪统一的MRI协议的偏差显示所有序列的最大相对偏差为0.124,但在3T扫描仪上,MRI协议和扫描的变化导致了巨大的相对偏差,分别高达-0.357和-0.526。当3T扫描仪与1.5T扫描仪进行比较时,对肌肉的标准化减少了T1加权和T2加权序列的偏差,但没有减少ADC图的偏差。 


 兴趣区(ROI)的定位放置示例图在冠状位T1w TSE(A)和T2w STIR图像(B)中,ROI被放置在髂嵴的骨髓中以及相应层面上的梨状肌中。在两个位置测量B800信号强度和ADC:一次在髂嵴的骨髓(C,B800图像;E,ADC图),一次在骶骨的第一椎体(D,B800图像;F,ADC图)。对于每个B800/ADC的测量,在同一横向层面上的髂腰肌中放置一个ROI

本研究表明,具有相同场强和统一MRI方案的MRI扫描仪可以提供相对稳定的BM ADC和SI的定量测量。在应用ADC截断值时,应避免MRI场强和MRI方案的偏差以减少结果的误差。

原文出处:

Markus Wennmann,Heidi Thierjung,Fabian Bauer,et al.Repeatability and Reproducibility of ADC Measurements and MRI Signal Intensity Measurements of Bone Marrow in Monoclonal Plasma Cell Disorders: A Prospective Bi-institutional Multiscanner, Multiprotocol Study.DOI:10.1097/RLI.0000000000000838

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051820, encodeId=f2ac205182087, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Sep 05 00:22:08 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660281, encodeId=0ef71660281f7, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Sat Aug 06 18:22:08 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751567, encodeId=64dd1e5156726, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Fri Dec 09 01:22:08 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080548, encodeId=06832080548a6, content=<a href='/topic/show?id=d1e6361419e' target=_blank style='color:#2F92EE;'>#单克隆浆细胞疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36141, encryptionId=d1e6361419e, topicName=单克隆浆细胞疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed May 03 11:22:08 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466642, encodeId=a02e14666421d, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Mon Jul 18 02:22:08 CST 2022, time=2022-07-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051820, encodeId=f2ac205182087, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Sep 05 00:22:08 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660281, encodeId=0ef71660281f7, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Sat Aug 06 18:22:08 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751567, encodeId=64dd1e5156726, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Fri Dec 09 01:22:08 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080548, encodeId=06832080548a6, content=<a href='/topic/show?id=d1e6361419e' target=_blank style='color:#2F92EE;'>#单克隆浆细胞疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36141, encryptionId=d1e6361419e, topicName=单克隆浆细胞疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed May 03 11:22:08 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466642, encodeId=a02e14666421d, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Mon Jul 18 02:22:08 CST 2022, time=2022-07-18, status=1, ipAttribution=)]
    2022-08-06 aids221
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051820, encodeId=f2ac205182087, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Sep 05 00:22:08 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660281, encodeId=0ef71660281f7, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Sat Aug 06 18:22:08 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751567, encodeId=64dd1e5156726, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Fri Dec 09 01:22:08 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080548, encodeId=06832080548a6, content=<a href='/topic/show?id=d1e6361419e' target=_blank style='color:#2F92EE;'>#单克隆浆细胞疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36141, encryptionId=d1e6361419e, topicName=单克隆浆细胞疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed May 03 11:22:08 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466642, encodeId=a02e14666421d, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Mon Jul 18 02:22:08 CST 2022, time=2022-07-18, status=1, ipAttribution=)]
    2022-12-09 珙桐
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051820, encodeId=f2ac205182087, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Sep 05 00:22:08 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660281, encodeId=0ef71660281f7, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Sat Aug 06 18:22:08 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751567, encodeId=64dd1e5156726, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Fri Dec 09 01:22:08 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080548, encodeId=06832080548a6, content=<a href='/topic/show?id=d1e6361419e' target=_blank style='color:#2F92EE;'>#单克隆浆细胞疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36141, encryptionId=d1e6361419e, topicName=单克隆浆细胞疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed May 03 11:22:08 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466642, encodeId=a02e14666421d, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Mon Jul 18 02:22:08 CST 2022, time=2022-07-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2051820, encodeId=f2ac205182087, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Sep 05 00:22:08 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660281, encodeId=0ef71660281f7, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Sat Aug 06 18:22:08 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751567, encodeId=64dd1e5156726, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Fri Dec 09 01:22:08 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080548, encodeId=06832080548a6, content=<a href='/topic/show?id=d1e6361419e' target=_blank style='color:#2F92EE;'>#单克隆浆细胞疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36141, encryptionId=d1e6361419e, topicName=单克隆浆细胞疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed May 03 11:22:08 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466642, encodeId=a02e14666421d, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Mon Jul 18 02:22:08 CST 2022, time=2022-07-18, status=1, ipAttribution=)]

相关资讯

驯鹿生物与信达生物共同开发的全人源BCMA CAR-T细胞伊基仑赛注射液新药申请上市

伊基仑赛注射液是国内第一款全流程自主研发的CAR-T细胞治疗产品,由驯鹿生物和信达生物联合开发。这是国内首家递交新药上市获受理并有望成为国内首款获批的靶向BCMA的自体嵌合抗原受体T细胞免疫治疗产品。

Lancet Haematol:来那度胺+地塞米松±埃罗妥珠单抗治疗新发多发性骨髓瘤

埃罗妥珠单抗+来那度胺+地塞米松组和来那度胺+地塞米松组的中位无进展生存期分别是31.4个月和29.5个月

​精简版:2022年中国多发性骨髓瘤诊治指南更新要点,一目了然

中国多发性骨髓瘤诊治指南更新要点,重点解读!

Cancer Med:肺动脉高压是新诊断多发性骨髓瘤患者的不良预后因素

多发性骨髓瘤(MM)仍然是一种以浆细胞克隆增殖为特征的造血恶性肿瘤。随着MM治疗的进展,包括大剂量化疗后的自体造血干细胞移植(ASCT) 、免疫调节药物、蛋白酶体抑制剂和单克隆抗体,都显著延长了患者的

J Clin Oncol:Ciltacabtagene autoleucel治疗复发/难治性多发性骨髓瘤的长期预后

采用Ciltacabtagene autoleucel治疗复发性或转移性多发性骨髓瘤可获得持久的缓解